Cystatin C is more than GFR, and this may be a good thing.

Renal Physiol 293: F1423–F1432, 2007 18. Shillingford JM, Piontek KB, Germino GG, Weimbs T: Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 21: 489–497, 2010 19. Lieberthal W, Levine JS: The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 20: 2493–2502, 2009 20. Boehlke C, Kotsis F, Patel V, Braeg S, Voelker H, Bredt S, Beyer T, Janusch H, Hamann C, Godel M, Muller K, Herbst M, Hornung M, Doerken M, Kottgen M, Nitschke R, Igarashi P, Walz G, Kuehn EW: Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol 12: 1115–1122, 2010 21. Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, Parfrey P, Pei Y: Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 20: 1833–1838, 2009